BPTH Profile
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company based in the United States. The company leverages its proprietary DNAbilize technology, an innovative drug delivery and antisense technology platform. This platform utilizes P-ethoxy, a deoxyribonucleic acid (DNA) backbone modification designed to protect the DNA from degradation, enhancing the stability and efficacy of therapeutic agents. Bio-Path's approach aims to develop targeted therapies that can effectively treat various forms of cancer by silencing specific genetic pathways involved in disease progression.
The company's lead drug candidate, prexigebersen, is currently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Prexigebersen is an RNAi therapeutic that targets and inhibits the protein GRB2, which plays a crucial role in the proliferation and survival of cancer cells. By inhibiting GRB2, prexigebersen aims to induce cancer cell death and enhance the effectiveness of existing chemotherapies, offering a potential new treatment option for patients with these aggressive hematologic malignancies.
In addition to prexigebersen, Bio-Path is developing several other promising drug candidates. Liposomal Bcl-2 is being evaluated for the treatment of refractory and relapsed lymphoma and chronic lymphocytic leukemia. This drug targets the Bcl-2 protein, which is involved in preventing cancer cell apoptosis. Another key program is Liposomal STAT3, a preclinical stage drug designed to treat pancreatic cancer, non-small cell lung cancer, and AML by inhibiting the STAT3 protein, which is implicated in cancer cell growth and survival. Furthermore, prexigebersen-A is being developed for various solid tumors, expanding the potential applications of Bio-Path’s core technology.
Founded in 2007 and headquartered in Bellaire, Texas, Bio-Path Holdings, Inc. continues to advance its pipeline of RNAi-based therapies with the goal of providing new, effective treatments for patients with difficult-to-treat cancers. The company’s innovative approach to drug development, focusing on the use of DNAbilize technology, positions it at the forefront of the oncology therapeutic landscape, striving to make a significant impact on cancer treatment and patient outcomes.
|
